Merck, 442640-25MG, L3MBTL1 Ligand, UNC669

General description
A nicotinamido-pyrrolidine compound that targets the second MBT (Malignant Brain Tumor) module of "chromatin lock" L3MBTL1 (Lethal 3 MBT-Like protein 1; Kd = 5 µM by Isothermal titration calorimetry) that "reads"/binds mono- and dimethyl-lysine modified histones as well as other proteins involved in transcription, such as p53 and Rb, via methylation-dependent recognition. Shown to effectively compete against FAM-labeled, monomethylated Histone H3 (1-15) peptide (H3K9Me₁) binding to L3MBTL1 (Kd = 10 µM in a FP displacement assay) and exhibit higher affinity toward L3MBTL1 than L3MBTL3 and L3MBTL4 (IC₅₀ = 6, 35, and 69 µM, respectively, in a luminescent peptide competitive binding assay), while displaying no detectable binding toward four other methyl-lysine-binding proteins, the BMT domain-containing SFMBT1 and MBTD1, the PHD (Plant Homeodomain) finger-containing PHF13 (PHD finger 13), and the chromo domain-containing CBX7 (chromobox 7). As of end of 2012, no published data is available regarding the molecule′s permeability or biological activity in cells.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Herold, J.M., et al. 2011. J. Med. Chem.54, 2504.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)